Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

BACKGROUND: The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy was superior to placebo for patients with pretreated advanced gastric or gastroesophageal junction cancer, but early progression of tumors in some patients was of concern. METHODS: This post hoc analysis statistically...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yoon-Koo, Morita, Satoshi, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Sameshima, Hiroki, Chen, Li-Tzong, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732926/
https://www.ncbi.nlm.nih.gov/pubmed/34480657
http://dx.doi.org/10.1007/s10120-021-01230-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732926/
https://www.ncbi.nlm.nih.gov/pubmed/34480657
http://dx.doi.org/10.1007/s10120-021-01230-4

Ejemplares similares